Table 1 Key enhanced cellular therapies in clinical trials
From: Enhanced cellular therapy: revolutionizing adoptive cellular therapy
Title | Sponsors and collaborators | First posted | Phase | Conditions | Category | Trial number |
|---|---|---|---|---|---|---|
Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas | Abramson Cancer Center of the University of Pennsylvania | January 8, 2016 | phase 1/2 | CD19 + Diffuse Large B-cell Lymphomas, Follicular Lymphomas, Mantle Cell Lymphomas | PD-1 inhibitor-enhanced CAR-T cell therapy | NCT02650999 |
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | PACT Pharma, Inc | May 31, 2019 | Phase 1 | Solid Tumor | PD-1 inhibitor-enhanced TCR-T cell therapy | NCT03970382 |
RTX-240 Monotherapy and in Combination With Pembrolizumab | Rubius Therapeutics | May 4, 2020 | phase 1/2 | Solid Tumor, AML Adult | PD-1 inhibitor-enhanced erythrocyte cell therapy | NCT04372706 |
Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia (R/R-ALL) | The First Affiliated Hospital of Soochow University | September 1, 2020 | Phase 2 | B-cell Acute Lymphoblastic Leukemia | IFN-α-enhanced CAR-T cell therapy | NCT04534634 |
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto + Solid Tumors | Memorial Sloan Kettering Cancer Center | July 15, 2015 | Phase 1 | Solid Tumor | Cyclophosphamide-enhanced TRUCK CAR-T cell therapy | NCT02498912 |
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | May 11, 2020 | Phase 1 | Diffuse Large B-cell Lymphoma | IL7 and CCL19-enhanced CAR-T cell therapy | NCT04381741 |
A Study of DeTIL-0255 in Adults With Advanced Malignancies | Nurix Therapeutics, Inc | November 4, 2021 | Phase 1 | Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer | PROTAC-enhanced TIL therapy | NCT05107739 |
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | Baylor College of Medicine | November 14, 2018 | Phase 1 | Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor | Oncolytic Adenovirus-enhanced CAR-T cell therapy | NCT03740256 |